193 related articles for article (PubMed ID: 22160267)
1. A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.
Garnacho C; Serrano D; Muro S
J Pharmacol Exp Ther; 2012 Mar; 340(3):638-47. PubMed ID: 22160267
[TBL] [Abstract][Full Text] [Related]
2. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
3. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
Bhowmick T; Berk E; Cui X; Muzykantov VR; Muro S
J Control Release; 2012 Feb; 157(3):485-92. PubMed ID: 21951807
[TBL] [Abstract][Full Text] [Related]
4. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.
Hsu J; Rappaport J; Muro S
Pharm Res; 2014 Jul; 31(7):1855-66. PubMed ID: 24558007
[TBL] [Abstract][Full Text] [Related]
5. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
6. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
Papademetriou I; Tsinas Z; Hsu J; Muro S
J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.
Mane V; Muro S
Int J Nanomedicine; 2012; 7():4223-37. PubMed ID: 22915850
[TBL] [Abstract][Full Text] [Related]
8. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Hsu J; Northrup L; Bhowmick T; Muro S
Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
[TBL] [Abstract][Full Text] [Related]
9. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.
Kim J; Sinha S; Solomon M; Perez-Herrero E; Hsu J; Tsinas Z; Muro S
Biomaterials; 2017 Dec; 147():14-25. PubMed ID: 28923682
[TBL] [Abstract][Full Text] [Related]
10. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
Muro S; Dziubla T; Qiu W; Leferovich J; Cui X; Berk E; Muzykantov VR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1161-9. PubMed ID: 16505161
[TBL] [Abstract][Full Text] [Related]
11. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
12. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
Muro S; Garnacho C; Champion JA; Leferovich J; Gajewski C; Schuchman EH; Mitragotri S; Muzykantov VR
Mol Ther; 2008 Aug; 16(8):1450-8. PubMed ID: 18560419
[TBL] [Abstract][Full Text] [Related]
13. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S
J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213
[TBL] [Abstract][Full Text] [Related]
14. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs.
Muro S; Gajewski C; Koval M; Muzykantov VR
Blood; 2005 Jan; 105(2):650-8. PubMed ID: 15367437
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
Muro S; Schuchman EH; Muzykantov VR
Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
[TBL] [Abstract][Full Text] [Related]
16. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
Calderon AJ; Bhowmick T; Leferovich J; Burman B; Pichette B; Muzykantov V; Eckmann DM; Muro S
J Control Release; 2011 Feb; 150(1):37-44. PubMed ID: 21047540
[TBL] [Abstract][Full Text] [Related]
17. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.
Hsu J; Hoenicka J; Muro S
Pharm Res; 2015 Apr; 32(4):1264-78. PubMed ID: 25319100
[TBL] [Abstract][Full Text] [Related]
18. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme.
Manthe RL; Loeck M; Bhowmick T; Solomon M; Muro S
J Control Release; 2020 Aug; 324():181-193. PubMed ID: 32389778
[TBL] [Abstract][Full Text] [Related]
19. Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells.
Harley SL; Sturge J; Powell JT
Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):652-8. PubMed ID: 10712387
[TBL] [Abstract][Full Text] [Related]
20. Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.
Ghaffarian R; Bhowmick T; Muro S
J Control Release; 2012 Oct; 163(1):25-33. PubMed ID: 22698938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]